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2Abstract 
Ghrelin was purified from rat stomach as an endogenous ligand for the growth hormone 
secretagogue (GHS) receptor. As a GHS, ghrelin stimulates GH release, but it also has 
additional activities, including stimulation of appetite and weight gain. Plasma GH and 
ghrelin secretory patterns appear unrelated whereas many studies have correlated ghrelin 
variations with food intake episodes. In order to evaluate the role of endogenous ghrelin, GH 
secretion and food intake were monitored in male rats infused subcutaneously (6 µg/h during 
10 h) or intracerebroventrically (5 µg/h during 48 h) with BIM-28163, a full competitive 
antagonist of the GHS-R1a receptor. Subcutaneous BIM-28163 infusion significantly 
decreased GH area under the curve during a 6 hour sampling period by 54% and peak 
amplitude by 46%. Twelve hours after the end of treatment these parameters returned to 
normal. Central treatment was similarly effective [-37% and 42% for AUC and –44% and 
49% for peak amplitude on the first and second days of infusion, respectively]. Neither 
peripheral nor central BIM-28163 injection modifies GH peak number, GH nadir or IGF-1 
levels. In this protocol, food intake is not strongly modified and water intake is unchanged. 
Subcutaneously infusion of BIM-28163 did not change plasma leptin and insulin levels 
evaluated at 12:00 h and 16:00 h. On the contrary, central BIM-28163 infusion slightly 
increased leptin and significantly increased insulin concentrations. Thus, endogenous ghrelin, 
through GHS-R1a, acts as a strong endogenous amplifier of spontaneous GH peak amplitude.  
The mechanisms by which ghrelin modifies food intake remain to be defined, and may 
involve a novel GHS receptor. 
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3Introduction 
The secretory pattern of growth hormone (GH) is mainly driven by two counter-regulatory 
neurohormones, GH-releasing hormone (GHRH) and somatostatin (SRIH). However, the 
existence of a third factor regulating GH rhythmicity was suggested 20 years ago when met-
enkephalin analogues without opiate-like activity were found to exert potent GH-releasing 
activity (1). Since then, numerous synthetic GH secretagogues (GHS) have been developed 
and shown to act through a specific G-protein coupled receptor : GHS-R1a (2). GHS-R1a is 
distinct from the GHRH receptor and it is mainly expressed in the hypothalamus and pituitary 
gland. In 1999, a 28 amino acid acylated peptide was identified as an endogenous ligand for 
the GHS-R1a and termed ghrelin (3).  It has been demonstrated that the acylation is essential 
for GHS-R1a binding. Ghrelin is produced mainly by A-like cells in oxyntic glands of the 
stomach and it is secreted into the bloodstream (4).  In addition to the gastro-intestinal tract, 
ghrelin expression, at either the mRNA or protein level or both, has been identified in a 
number of tissues, including the hypothalamus (5). In this brain structure, low levels of 
ghrelin have been measured in the arcuate nucleus (3, 6) which is involved in the control  of 
GH secretion and food intake. As expected ghrelin stimulates GH release (3, 4, 7-9) but also 
exerts multiple activities, including increased feeding (9) and weight gain (10).  The 
circulating levels and patterns of ghrelin and GH appear weakly related (11) whereas many 
studies have established strong correlations between ghrelin variations and food intake 
episodes. Fasting increases circulating ghrelin levels which decrease after food intake (11-13). 
Ghrelin gene deletion in mice impairs neither growth nor appetite (14, 15) though deleting the 
GHS-R gene does abolish both ghrelin and synthetic GHS effects on these two functions (16). 
Thus, the role of endogenous ghrelin in the regulation of pulsatile GH secretion and food 
intake is not yet clear.  The aim of the present study was to define this role by examining the 
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4effects of treating rats with a novel analog of ghrelin, BIM-28163, recently developed as a full 
competitive antagonist of the GHS-R1a (17).
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1) In vitro experiments :
 Binding Assay
The cDNA of the human GHS-R1a was cloned by polymerase chain reaction (PCR) using 
human brain RNA (Clontech, Palo Alto, CA, USA) as the template.  The PCR product was 
cloned into the pCR2.1 vector using the TA Cloning Kit (Invitrogen, Carlsbad, CA, USA), 
and subcloned into the mammalian expression vector pcDNA 3.1 (Invitrogen).  The plasmid 
was transfected into the Chinese hamster ovary cell line, CHO-K1 (ATCC, Manassas, VA, 
USA), by the calcium phosphate method.  Single cell clones stably expressing the human 
GHS-R1a were obtained by selecting transfected cells using 0.8 mg/ml G418 containing 
selection media (Life Technologies, Carlsbad, CA, USA).  
Membranes were prepared for radioligand binding studies by homogenization of CHO-K1 
cells expressing the human recombinant GHS-R1a in 20 ml of ice-cold 50 mM Tris-HCl with 
a Brinkman Polytron (Westbury, NY, USA) (setting 6, 15 sec).  The homogenates were 
washed twice by centrifugation (39,000 g for 10 min), and the final pellets were resuspended 
in 50 mM Tris-HCl, containing 2.5 mM MgCl2, and 0.1% BSA.  For assay, aliquots (0.4 ml) 
were incubated with 0.05 nM [125I]h-ghrelin (~2000 Ci/mmol), with and without 0.05 ml of 
unlabeled competing test peptide.  After a 60 min incubation (4 °C), the bound [125I]h-ghrelin 
was separated from the free by rapid filtration through GF/C filters (Brandel, Gaithersburg, 
MD, USA), which had been previously soaked in 0.5% polyethyleneimine/0.1% BSA.  The 
filters were then washed three times with 5-ml aliquots of ice-cold 50 mM Tris-HCl and 0.1% 
bovine serum albumin, and the bound radioactivity trapped on the filters was counted by 
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as the total [125I]h-ghrelin bound minus that bound in the presence of 1000 nM unlabeled h-
ghrelin (Bachem, Torrence, CA, USA). 
Intracellular Calcium Mobilization Assay 
CHO-K1 cells, expressing the GHS-R1a, were harvested by incubating in a 0.3% 
EDTA/phosphate buffered saline solution (25 °C), and washed twice by centrifugation.  The 
washed cells were resuspended in Hank's - buffered saline solution (HBSS) for loading of the 
fluorescent calcium indicator Fura-2AM.  Cell suspensions of approximately 106 cells/ml 
were incubated with 2 mM Fura-2AM for 30 min at 25 °C.  Unloaded Fura-2AM was 
removed by centrifugation twice in HBSS, and the final suspensions were transferred to a 
spectrofluorometer (Hitachi F-2000) equipped with a magnetic stirring mechanism and a 
temperature-regulated cuvette holder.  After equilibration to 37 °C, the h-ghrelin analogues 
were added for measurement of intracellular calcium mobilization. The excitation and 
emission wavelengths were 340 and 510 nm, respectively.
2) In vivo experiments 
Acute in vivo GH stimulation
Male Sprague-Dawley rats (250g) were anesthetized and fit with a jugular-right atrial 
cannula 18 h prior to the experiment.  To determine basal hormone levels blood samples 
were withdrawn into heparinized syringes at time -10 and 0.  To demonstrate antagonist 
activity, immediately after the time 0 blood sample, the rats were injected with either BIM-
28163 (1000 µg/kg) or vehicle via the indwelling cannula. Ten minutes later, a blood sample 
was withdrawn and the rats were immediately injected with either h-ghrelin (10 µg/kg) or 
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7vehicle via the cannula. Subsequent blood samples were withdrawn 10, 20 and 40 minutes 
post-injection of h-ghrelin or vehicle. Plasma was separated and stored until assay for GH. 
Chronic in vivo treatments
Four weeks before sampling experiments, adult male Sprague Dawley rats weighing 100–125 
g (Charles River Laboratories, Inc., L’arbresle, France) were housed individually in 
transparent plastic containers placed in a soundproof room with controlled temperature (22-
24 °C) and illumination (12 h light, 12 h dark schedule with lights off at 19:00 h). They had 
free access to food and water and were regularly handled and weighed, to minimize stress 
effects. Guidelines of the National Institute of Health for the Care and Use of Laboratory 
Animals [1996 (7th ed.) Washington, DC: National Academy Press, aka National Research 
Council Guide.] were followed. 
SC treatment
Six days before the experiment, an osmotic minipump (Alzet Model 2002, flow rate 0.5 µl/h 
for 14 days; Charles River, France) was connected to a polyethylene catheter and implanted 
subcutaneously in the back of the animals under ether anaesthesia. The catheter had 
previously been filled with a combination of saline and BIM or saline. This resulted in 
delivery of saline during 144 hours followed by BIM-28163 (6 µg/h) or saline during 10 
hours. On the day of the experiment (d0) SC treatment started at 9:00 h and rats received IP 
injection of 300 µg/0.2 ml BIM-28163 or 0.2 ml NaCl at 10:00 h. 
ICV treatment
Six days before the experiment, a chronic ICV cannula (Alzet Brain Infusion Kit II, Charles 
River, France) was inserted into the lateral ventricle of the brain under pentobarbital 
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coordinates were used: anterior -0.8 mm to the bregma; lateral -1.5 mm to the midline; height 
-3.8 mm to the bregma, with the incisor bar set at -3.3 mm below the interaural line. The 
cannula was secured to the skull of the animal with stainless steel and dental cement and 
connected to an osmotic minipump (Alzet Model 2002; flow rate 0.5 µl/h for 14 days Charles 
River) implanted under the dorsal skin of the animal. The flow moderator of the pump was 
connected to the polyethylene catheter containing 72 µl saline, which was administered 
during the first 6 days in all animals. A small air bubble was inserted to separate the saline 
solution from an additional 24 µl of BIM-28163 (5 µg/h) or saline to be delivered for an 
additional 48 h. Treatment started at 8:00 h on d0 until 8:00 h on d2. 
Blood sampling schedule  
Experiments were performed on freely moving rats. Two days before data collection, an 
indwelling cannula was inserted into the right atrium under ether anesthesia as previously 
described (18). Two hours before the sampling and recording period, the distal extremity of 
the cannula was connected to a polyethylene catheter filled with 25 IU/ml heparinized saline. 
Blood samples were withdrawn every 20 minutes and centrifuged immediately. Red blood 
cells were resuspended in saline and reinjected every hour to attenuate hemodynamic 
modifications. Plasma was stored at -20 °C until assayed for GH. 
Feeding behaviour 
Experiments on food and water intake were performed on a separate group of animals which 
underwent the same treatments. Food and water intake were measured continuously with a 
PC-controlled monitoring system (Feeding/Drinking Monitor, Technical & Scientific 
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1 week before actual monitoring. 
3) Hormonal determinations 
Plasma GH concentrations were measured by EIA as previously described (19). Values are 
reported in terms of rGH-RP2, with sensitivity of 5 ng/ml and intra- and interassay 
coefficients of variation below 7%.
Plasma insulin, total leptin and IGF-1 levels were determined with RIA kits following 
manufacturer instructions (Linco, Saint Charles, Missouri ; DSL, Webster, Texas, USA, 
respectively). The sensitivity was 0.2 ng/ml, 0.5 ng/ml and 160 ng/ml respectively. For all 
assays, the intra- and interassay coefficients of variation were below 10%. 
4) Statistical analysis
GH pulse analysis was performed using the Cluster program (20) with the t value set to 2 to 
maintain false positive rates under 1%. Cluster size was set to two prepeak and two postpeak 
nadir values. False positive error for peak detection was 7%. 
Areas under the GH response curves (AUC) were calculated by mean of trapezoidal analysis. 
Values are given as means ± SEM and statistical analysis was performed by ANOVA and 
paired t test using the JMP IN 5.1 software (SAS Institute Inc, North Carolina, USA). 
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Results 
1) In vitro experiments 
BIM-28163 was found to displace labelled h-ghrelin binding to the human GHS-R1a with a 
IC50 (Ki) of 8.1 + 1.3 nM.  Human ghrelin, under the same conditions, had an IC50 of 1.6 +
0.3 nM.
In the calcium mobilization assay, h-ghrelin induced concentration-dependent calcium 
mobilization in cells stably transfected with the human GHS-R1a between the concentrations 
of 0.1 and 100nM, with an EC50 of 5.4 + 1.4nM.  In contrast, BIM-28163 had no effect on 
calcium mobilization, even when tested at concentrations as high as 10-6 M (data not shown).  
When added in combination, BIM-28168 attenuated the ability of h-ghrelin to induce 
calcium mobilization in a dose-dependent manner, with complete inhibition achieved with a 
ratio of 100:1 BIM-28163:h-ghrelin (Figure 1), indicating that BIM-28163 acts as a full, 
competitive antagonist of ghrelin at the GHS-R1a.  
Neither [125I]h-ghrelin binding nor ghrelin-induced mobilization of intracellular calcium was 
observed in the parent CHO-K1 cell line. 
2) In vivo experiments 
Acute in vivo GH stimulation 
Ghrelin induced GH stimulation was maximal 10 minutes post injection (data not shown). As 
illustrated on Figure 2, injection of h-ghrelin (10 µg/kg) alone into freely-moving, 
unanesthetized rats induced a significant increase in plasma GH, whereas injection of BIM-
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28163 (1000 µg/kg) was without effect.  When BIM-28163 was injected 10 minutes prior to 
h-ghrelin, the h-ghrelin-induced increase in GH secretion was completely abolished.   
Chronic in vivo treatments 
BIM-28163 was infused either SC (at the rate of 6 µg/h during 10 h after an IP bolus of 300 
µg) or ICV (at the rate of 5 µg/h during 48h) to unanaesthetized, freely-moving rats and 
blood samples were collected every 20 minutes for 6 hours the first day, one hour after the 
beginning of infusion, and the following day during the same period. Individual profiles are 
illustrated on Figure 3. BIM-28163 administration always resulted in a rapid decrease in 
spontaneous GH release. Throughout BIM-28163 treatment, total GH, calculated as area 
under the curve, was significantly lower in treated animals compared with their respective 
controls (table 1). The decrease in total GH corresponded to a similar decrease in GH peak 
amplitudes.  Basal values and GH pulse number were not modified (Table 1). ICV infusion 
was similarly effective on the first and second day of treatment. Fifteen hours after the end of 
SC treatment, pulsatile GH secretion was similar to that of controls. 
 Neither SC nor ICV treatment modified plasma IGF-1 levels, sampled at 15:00 h [SC 
treatment: BIM-28163 = 779 ± 84 ng/ml (n=5) vs. saline = 855 ± 78 ng/ml; ICV treatment: 
BIM-28163 = 977 ± 94 ng/ml (n=7) vs. saline = 1105 ± 133 ng/ml (n=7) on the first day, and 
BIM-28163 = 1199 ± 96 ng/ml (n=7) vs. saline =1162 ± 113 ng/ml (n=7) on the second day]. 
SC infusion of BIM-28163 changed neither plasma leptin nor insulin levels evaluated at 
12:00 h and 16:00 h. In contrast, ICV BIM-28163 infusion slightly increased leptin and 
significantly increased insulin concentrations (Table 2). 
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Food intake was modestly increased only during the light-on period on the second day after 
ICV infusion of BIM-28163 (Figure 4) and water consumption remained unchanged after 
either peripheral or central BIM-28163 infusion. 
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Discussion 
In this study, either SC or ICV infusion of a GHS-R1a antagonist, BIM-28163, was 
demonstrated to decrease spontaneous GH secretion without causing major changes in food 
intake. This h-ghrelin analog is a full competitive antagonist at the GHS-R1a.  Indeed, BIM-
28163 binds to the h-GHS-R1a receptor and can displace h-ghrelin binding, but BIM-28163 
does not activate GHS-R1a and completely and dose-dependently inhibits the ability of 
ghrelin to stimulate calcium mobilization in h-GHS-R1a transfected cells and GH secretion 
in vivo. Morever BIM-28163 blunts the GH releasing effect of ghrelin but not the GHRH 
induced GH rise (17).  Thus, our results indicate that ghrelin, acting through the GHS-R1a, 
appears to be an endogenous regulator of spontaneous GH secretion but not necessarily of 
food intake.   
Interestingly, antagonism of the GHS-R1a in freely-moving male rats does not impair the 
pulsatile pattern of GH secretion; however, it significantly lowers pulse amplitude. These 
results suggest that endogenous ghrelin acts to amplify the basic pulsatile pattern of GH 
established by the interplay of hypothalamic GHRH and somatostatin (21).  Indeed, it has 
been established that concomitant administration of ghrelin and GHRH produces an increase 
in GH secretion significantly greater than that induced by either factor alone (22).  The 
observation that antagonism of the GHS-R1a receptor with BIM-28163 lowers spontaneous 
GH pulse amplitude and total GH secretion without altering the basic pulsatile pattern agrees 
well with the observation of (23) that treatment of elderly men with MK677, a non-peptide 
ligand and agonist of the GHS-R1a, results in a significant increase in GH secretion without 
changing the underlying pulsatile pattern.  Previously, repetitive injections of [D-Lys3]- 
GHRP6, a compound reported to be a GHS-R1a antagonist, did not significantly reduce 
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plasma GH levels (24); however, a very low dose of [D-Lys3]-GHRP6 was used (750 ng, less 
than one nanomole) considering the in vitro IC50 (3.2 x 10-6 M) of this particular analog (25) 
and its minimum effective dose on in vivo food intake (200 nM) (26). On the other hand, GH 
secretion was reduced in female (but not in male) transgenic rats expressing an antisense 
GHS-R mRNA under the control of the tyrosine hydroxylase promoter, thus selectively 
attenuating GHS-R protein expression in the arcuate nucleus (27). Moreover, in ghsr-null
mice serum IGF-1 levels and body weight are reduced compared with wild type littermates 
suggesting decreased GH secretion (16). Taken together, these data suggest that endogenous 
ghrelin (or another, yet unidentified, ligand of GHS-R1a) acts as an amplifier of GH 
pulsatility.  At the present time, a strict correlation has not been established between GH and 
ghrelin secretory episodes (11); however, only total ghrelin was monitored and it cannot be 
excluded that a stronger correlation occurs between GH and acylated ghrelin which 
represents only a minor proportion of total plasma ghrelin and has a very short half life (28).  
In the subchronic experimental paradigm used herein, total plasma IGF-1 levels were not 
modified by BIM-28163 infusion. This lack of effect is in keeping with the data obtained on 
male transgenic rats expressing an antisense GHS-R mRNA in the arcuate nucleus (27) as 
well as another study in which chronic ICV administration of ghrelin for seven days did not 
affect IGF-1 levels (29). Moreover, 95% of IGFs circulate bound to IGFBPs and have a half 
life of 12-15 hours (30, 31); thus, it cannot be excluded that a longer treatment might affect 
IGF-1 levels. 
Interestingly, plasma leptin slightly and insulin concentrations were significantly elevated by 
ICV BIM-28163 treatment, but not by peripheral administration.  The change in plasma 
leptin concentrations may represent triggering of counter regulatory mechanisms as leptin 
has been reported to suppress feeding; although the overt effect of ghrelin on feeding in the 
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present study was minimal.  Surprisingly, the effect on insulin secretion was only observed 
following ICV administration of BIM-28163.  Expression of the GHS-R1a has been 
described in the pancreas, yet direct interaction with BIM-28163 via peripheral 
administration produced no significant effect on insulin secretion.  Results from both GHS-R
(16) and ghrelin null (14) mice also suggest that ghrelin exerts only  a minimal role in 
regulating insulin or leptin levels, as these parameters remain largely unchanged in both 
animal models. Indeed the relationship between ghrelin and insulin secretion is far from clear 
as, depending on the dose, model and species, ghrelin has been reported to both stimulate and 
suppress insulin secretion (32). The present results may suggest a central mechanism for 
stimulation of insulin secretion, as well as provide evidence that this analog does not cross 
the blood brain barrier; however, further knowledge is clearly needed to fully interpret the 
present results on leptin and insulin secretion.  
The fact that BIM-28163 treatment, either ICV or SC, does not change feeding behaviour is 
surprising since both GH secretagogues and exogenous ghrelin do stimulate food intake via 
GHS-R1a (16). Moreover, suppression of feeding has been reported in mice after ICV 
injections, using two other antagonists: [D-Lys3]-GHRP6, an analog of one of the synthetic 
GHSs or [D-Arg,D-Phe,D-Trp,Leu]-substance P an analog of substance P (26). Results with 
these compounds may be difficult to interpret as the first also binds to four of the 
melanocortin receptors (33) and the second antagonizes many peptide receptors (34, 35). A 
recent report indicated that the GHS-R1a displays a high constitutive activity and that  [D-
Arg,D-Phe,D-Trp,Leu]-substance P is a full inverse agonist, rather than a true antagonist 
(36). One might therefore hypothesize that the GHS-R1a involved in GH regulation and in 
food intake may have different levels of constitutive activity and, subsequently, different 
responses to inverse agonists and antagonists.  Alternatively, it cannot be excluded that 
another, as yet unknown, ghrelin receptor may exist.  Structural variants of GHS-R have been 
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found in human, swine, chicken and fish genome (37-39).  A truncated version of the GHS 
receptor, derived from alternative gene splicing, GHS-R 1b, and not yet observed in the rat, 
cannot be the novel ghrelin receptor since it binds neither ghrelin nor any of the various GHS 
molecules. However, GHS-R 1b, or another receptor, may interact with GHS-R1a, perhaps 
through receptor heterodimerization as shown in fish (39), thereby playing a counter 
regulatory role in controlling either GH secretion or food intake.  
Another potential explanation of the discrepant results using GHS-R1a antagonists may rely 
on the central or peripheral location of the ghrelin systems involved. Central ghrelin probably 
stimulates food intake and GH secretion through neural mechanisms involving neuronal 
circuitry (40). An important site for GHS-R1a mediation of GH secretion is the hypothalamic 
arcuate nucleus (41), where GHS-R mRNA is expressed on both GHRH and NPY-expressing 
neurons (21). However, peripheral ghrelin can also modulate food intake and GH secretion 
via vagal afferent fibers (42).  Blockade of the vagal afferent, either through vagotomy or 
through perivagal capsaicin application, totally blocks peripheral ghrelin effects on feeding 
while it only attenuates the stimulation of GH secretion. 
In summary, this study shows that pharmacological dissociation of the effects of endogenous 
ghrelin on GH secretion and feeding is possible. It will remain to be determined whether 
other effects of this interesting peptide, such as those on adiposity or cardiac function can 
also be separately affected. At any rate, the present data support the feasibility of creating 
ghrelin analogs with selective actions on either GH or feeding behavior. 
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Figure Legends 
Figure 1: Dose-related attenuation of the ability of h-ghrelin to stimulate calcium 
mobilization in CHO-K1 cells stably transfected with the human GHS-R1a by BIM-28163, a 
competitive, though non-activating, ligand for GHS-R1a.  
Each bar and bracket represents the mean + SEM of 3 replicate experiments. *** : p<0,001 vs 
ghreline; °°° : p<0,001 
Figure 2: Acute blockade by BIM-28163 of h-ghrelin stimulation of GH secretion in vivo
Data are presented as peak GH levels observed 10 minutes after the injection of either vehicle, 
h-ghrelin (10 µg/kg), BIM-28163 (1000 µg/kg), or the combination. *** :p<0.001 vs vehicle 
Figure 3: Representative GH secretory patterns during a 6-h sampling period in freely 
moving male rats that received subchronic SC (left panel) or ICV (right panel) administration 
of either BIM-28163 (open circles) or saline (closed squares).  
In the SC group, rats were infused at d0 with saline or BIM-28163 (6 µg/h) from 9:00 h to 
19:00 h and received an IP injection of saline or BIM-28163 (300µg) at 10:00 h. In the ICV 
group, rats were infused with saline or BIM-28163 (5 µg/h) for 48h from 8:00 h at d0. 
Blood samples were collected every 20 min.  
Figure 4: Effect of subchronic SC (left panel) or ICV (right panel) administration of BIM-
28163 (open symbols) or saline (closed symbols) on food intake.  
Upper panel: Cumulative food intake during the 48 h post infusion.  
H
AL author m
anuscript    inserm
-00117250, version 1
22 
Lower panel: Food intake measured during both the diurnal (7:00 h-19:00 h) and nocturnal 
period (19:00 h-7:00 h) before, during and after treatment. 
Table 1 : Cluster analysis of GH pulsatility parameters in BIM-28163-treated rats. 
In the SC group, rats were infused at d0 with saline or BIM-28163 (6 µg/h) from 9:00 h to 
19:00 h and received an injection of saline or BIM-28163 (300 µg) at 10:00 h. In the ICV 
group, rats were infused with saline or BIM-28163 (5 µg/h) for 48 h  from 8:00 h at d0. 
Data are mean ± sem. ** : p<0.01 ; * : p<0.05 vs saline 
Table 2 : Effect of subchronic BIM-28163 administration on insulin and leptin plasma levels. 
SC administration: Hormones were measured in freely moving male rats at 12:00 h and 16:00 
h on day 0 (d0: 3 h and 7 h after the start of the treatment) and at the same time on day 1 (d1: 
17 h and 21 h after the end of the treatment),  
ICV administration: Hormones were measured in freely moving male rats at 12:00 h and 
16:00 h on d0 (4 h and 8 h after the start of the treatment) and at the same time on d1 (28 h 
and 32 h after the start of the treatment),  
Data are mean ± sem.** : p<0.01; * : p<0.05 vs saline 
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